Circulating markers of bone turnover

Marc G. Vervloet, Vincent Brandenburg, on behalf of CKD-MBD working group of ERA-EDTA

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Renal osteodystrophy is a feature of chronic kidney disease (CKD), with increasing prevalence as CKD progresses. This bone disease is responsible for major morbidity, including fractures, and a deterioration in the quality of life and its sequelae. Circulating biomarkers of renal osteodystrophy typically indicate bone turnover, but not other features of bone, like bone volume, mineralization, quality or strength. Bone turnover can be considered to be primarily a reflection of bone cell activity, in particular that of osteoblasts and osteoclasts. Since current treatments for bone disease usually target cellular activity, biomarkers are considered to be able to contribute to the decision-making for treatment and its follow-up. In CKD, one has to consider the impact of a diminished clearance of biomarkers or their altered metabolism, both potentially limiting its clinical use. Here, several aspects of the most frequently used biomarkers of bone turnover are reviewed, with an emphasis on the specific situation represented by CKD. This review is based on the overview lecture at the symposium held in Amsterdam, September 23, 2016: “The Bone In CKD”, organized by the CKD-MBD working group of ERA-EDTA.

Original languageEnglish
Pages (from-to)663-670
Number of pages8
JournalJournal of Nephrology
Volume30
Issue number5
DOIs
Publication statusPublished - 1 Oct 2017

Cite this

Vervloet, M. G., Brandenburg, V., & on behalf of CKD-MBD working group of ERA-EDTA (2017). Circulating markers of bone turnover. Journal of Nephrology, 30(5), 663-670. https://doi.org/10.1007/s40620-017-0408-8
Vervloet, Marc G. ; Brandenburg, Vincent ; on behalf of CKD-MBD working group of ERA-EDTA. / Circulating markers of bone turnover. In: Journal of Nephrology. 2017 ; Vol. 30, No. 5. pp. 663-670.
@article{5e278165372d4123afca3a686eb19f55,
title = "Circulating markers of bone turnover",
abstract = "Renal osteodystrophy is a feature of chronic kidney disease (CKD), with increasing prevalence as CKD progresses. This bone disease is responsible for major morbidity, including fractures, and a deterioration in the quality of life and its sequelae. Circulating biomarkers of renal osteodystrophy typically indicate bone turnover, but not other features of bone, like bone volume, mineralization, quality or strength. Bone turnover can be considered to be primarily a reflection of bone cell activity, in particular that of osteoblasts and osteoclasts. Since current treatments for bone disease usually target cellular activity, biomarkers are considered to be able to contribute to the decision-making for treatment and its follow-up. In CKD, one has to consider the impact of a diminished clearance of biomarkers or their altered metabolism, both potentially limiting its clinical use. Here, several aspects of the most frequently used biomarkers of bone turnover are reviewed, with an emphasis on the specific situation represented by CKD. This review is based on the overview lecture at the symposium held in Amsterdam, September 23, 2016: “The Bone In CKD”, organized by the CKD-MBD working group of ERA-EDTA.",
keywords = "Biomarkers, Bone turnover, Chronic kidney disease, CKD-MBD",
author = "Vervloet, {Marc G.} and Vincent Brandenburg and Jordi Bover and Vincent Brandenburg and Adrian Covic and Mario Cozzolino and Pieter Evenepoel and David Goldsmith and Ziad Massy and Sandro Mazzaferro and Pablo Ūrena-Torres and Vervloet, {Marc G.} and {on behalf of CKD-MBD working group of ERA-EDTA}",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s40620-017-0408-8",
language = "English",
volume = "30",
pages = "663--670",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",
number = "5",

}

Vervloet, MG, Brandenburg, V & on behalf of CKD-MBD working group of ERA-EDTA 2017, 'Circulating markers of bone turnover' Journal of Nephrology, vol. 30, no. 5, pp. 663-670. https://doi.org/10.1007/s40620-017-0408-8

Circulating markers of bone turnover. / Vervloet, Marc G.; Brandenburg, Vincent; on behalf of CKD-MBD working group of ERA-EDTA.

In: Journal of Nephrology, Vol. 30, No. 5, 01.10.2017, p. 663-670.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Circulating markers of bone turnover

AU - Vervloet, Marc G.

AU - Brandenburg, Vincent

AU - Bover, Jordi

AU - Brandenburg, Vincent

AU - Covic, Adrian

AU - Cozzolino, Mario

AU - Evenepoel, Pieter

AU - Goldsmith, David

AU - Massy, Ziad

AU - Mazzaferro, Sandro

AU - Ūrena-Torres, Pablo

AU - Vervloet, Marc G.

AU - on behalf of CKD-MBD working group of ERA-EDTA

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Renal osteodystrophy is a feature of chronic kidney disease (CKD), with increasing prevalence as CKD progresses. This bone disease is responsible for major morbidity, including fractures, and a deterioration in the quality of life and its sequelae. Circulating biomarkers of renal osteodystrophy typically indicate bone turnover, but not other features of bone, like bone volume, mineralization, quality or strength. Bone turnover can be considered to be primarily a reflection of bone cell activity, in particular that of osteoblasts and osteoclasts. Since current treatments for bone disease usually target cellular activity, biomarkers are considered to be able to contribute to the decision-making for treatment and its follow-up. In CKD, one has to consider the impact of a diminished clearance of biomarkers or their altered metabolism, both potentially limiting its clinical use. Here, several aspects of the most frequently used biomarkers of bone turnover are reviewed, with an emphasis on the specific situation represented by CKD. This review is based on the overview lecture at the symposium held in Amsterdam, September 23, 2016: “The Bone In CKD”, organized by the CKD-MBD working group of ERA-EDTA.

AB - Renal osteodystrophy is a feature of chronic kidney disease (CKD), with increasing prevalence as CKD progresses. This bone disease is responsible for major morbidity, including fractures, and a deterioration in the quality of life and its sequelae. Circulating biomarkers of renal osteodystrophy typically indicate bone turnover, but not other features of bone, like bone volume, mineralization, quality or strength. Bone turnover can be considered to be primarily a reflection of bone cell activity, in particular that of osteoblasts and osteoclasts. Since current treatments for bone disease usually target cellular activity, biomarkers are considered to be able to contribute to the decision-making for treatment and its follow-up. In CKD, one has to consider the impact of a diminished clearance of biomarkers or their altered metabolism, both potentially limiting its clinical use. Here, several aspects of the most frequently used biomarkers of bone turnover are reviewed, with an emphasis on the specific situation represented by CKD. This review is based on the overview lecture at the symposium held in Amsterdam, September 23, 2016: “The Bone In CKD”, organized by the CKD-MBD working group of ERA-EDTA.

KW - Biomarkers

KW - Bone turnover

KW - Chronic kidney disease

KW - CKD-MBD

UR - http://www.scopus.com/inward/record.url?scp=85030528620&partnerID=8YFLogxK

U2 - 10.1007/s40620-017-0408-8

DO - 10.1007/s40620-017-0408-8

M3 - Review article

VL - 30

SP - 663

EP - 670

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 5

ER -

Vervloet MG, Brandenburg V, on behalf of CKD-MBD working group of ERA-EDTA. Circulating markers of bone turnover. Journal of Nephrology. 2017 Oct 1;30(5):663-670. https://doi.org/10.1007/s40620-017-0408-8